Paragon 28 (DB:7GQ) - Aandelenkoers, Nieuws & Analyse

7GQ Overzicht aandelen

Paragon 28, Inc. ontwikkelt, distribueert en verkoopt chirurgische systemen voor voeten en enkels in de Verenigde Staten en internationaal. Meer informatie

7GQ fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 13.97% per jaar groeien

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Paragon 28, Inc. Concurrenten

Eckert & Ziegler

XTRA:EUZ

€879.3m

Drägerwerk KGaA

XTRA:DRW3

€798.0m

Stratec

XTRA:SBS

€336.7m

Carl Zeiss Meditec

XTRA:AFX

€5.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Paragon 28
Historische aandelenkoersen
Huidige aandelenkoers	US$9.45
52 Week Hoogtepunt	US$13.30
52 Week Laag	US$4.06
Bèta	1.01
11 maand verandering	117.74%
3 maanden verandering	30.34%
1 Jaar Verandering	2.16%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-38.02%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	7GQ	DE Medical Equipment	DE Markt
7D	1.6%	2.4%	0.8%
1Y	2.2%	-5.0%	9.1%

Rendement versus industrie: 7GQ overtrof de German Medical Equipment industrie, die het afgelopen jaar een rendement -5 % opleverde.

Rendement versus markt: 7GQ presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 9.1 % opleverde.

Prijsvolatiliteit

Is 7GQ's price volatile compared to industry and market?
7GQ volatility
7GQ Average Weekly Movement	14.6%
Medical Equipment Industry Average Movement	5.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 7GQ is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van 7GQ is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	574	Albert DaCosta	paragon28.com

Paragon 28, Inc. ontwikkelt, distribueert en verkoopt chirurgische systemen voor voeten en enkels in de Verenigde Staten en daarbuiten. Het bedrijf biedt platsystemen, waaronder gorillaplatsystemen, zoals lisfranc-, lapidus-, laterale kolom-, calcaneusglij- en naviculocuneiforme (NC) fusieplatsystemen; baby gorillaplaat-specifieke schroeven, naviculare fractuurplaten en 5e metatarsale haakplaten; en silverback platsystemen. Het bedrijf levert ook precisiegeleidingstechnologie voor verschillende procedures, zoals fusie, een procedure om bunionmisvormingen aan te pakken waarbij twee botten van de grote teen samensmelten; eerste tarsometatarsale artrodese; en metatarsale osteotomie voor bunioncorrectie, mediale kolomstraal voor charcotvoetreconstructie, enkelfusieplaten en NC-gewrichtartrodese.

Paragon 28, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Paragon 28 zich tot de beurswaarde?
7GQ fundamentele statistieken
Marktkapitalisatie	€800.88m
Inkomsten(TTM)	-€53.50m
Inkomsten(TTM)	€233.43m

3.4x

P/S-verhouding

-14.7x

Koers/Winstverhouding

Is 7GQ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
7GQ resultatenrekening (TTM)
Inkomsten	US$245.00m
Kosten van inkomsten	US$55.11m
Brutowinst	US$189.89m
Overige uitgaven	US$246.03m
Inkomsten	-US$56.15m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.67
Brutomarge	77.51%
Nettowinstmarge	-22.92%
Schuld/Eigen Vermogen Verhouding	79.3%

Hoe presteerde 7GQ op de lange termijn?

Bekijk historische prestaties en vergelijking

7GQ Overzicht aandelen

Beloningen

Risicoanalyse

Paragon 28, Inc. Concurrenten

XTRA:EUZ

€879.3m

XTRA:DRW3

€798.0m

XTRA:SBS

€336.7m

XTRA:AFX

€5.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Recent updates

Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2023)

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2023)

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2023)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought €234k worth of stock

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.88 loss in FY 2022)

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

New minor risk - Share price stability

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.12 loss in 1Q 2022)

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.26 loss in FY 2021)

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 3Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold €1.1m worth of stock

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Paragon 28, Inc. Announces Board Changes

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.05 loss in 2Q 2021)

Paragon 28, Inc. Revises Revenue Guidance for the Full Year 2022

Paragon 28, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paragon 28, Inc.(NYSE:FNA) dropped from Russell 2500 Value Index

Key Executive recently sold €355k worth of stock